Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
about
Interventions for the management of oral ulcers in Behçet's diseaseClinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndromeBehçet's disease: a new target for anti-tumour necrosis factor treatmentBehçet's diseaseMucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future PerspectivesNeuro-Behçet's disease in childhood: a focus on the neuro-ophthalmological featuresIs Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality CheckA double-blind trial of depot corticosteroids in Behçet's syndromeBiological treatments in Behçet's disease: beyond anti-TNF therapy.Behcet's Syndrome.The treatment of chronic recurrent oral aphthous ulcers.Number VII Behçet's disease (Adamantiades syndrome).New Evidence-Based Treatment Approach in Behçet's Disease.Managing the symptoms of Behçet's disease.Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsOutcome measures used in clinical trials for Behçet syndrome: a systematic review.Recurrent versus non-recurrent or no eye involvement in Behcet's disease.Biologic therapies for inflammatory eye disease.Mucocutaneous lesions of Behcet's diseaseIntestinal complications of Behçet's diseaseManaging Behçet's disease: An update on current and emerging treatment options.Interferon-alpha in the management of patients with Behçet's disease.Interferons and their potential in the treatment of ocular inflammation.Short-Term Efficacy of Pudilan Keyanning Toothpaste in Treatment of Minor Recurrent Aphthous Ulcers.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.The great masquerader: Behcet's disease.Update on the therapy of Behçet disease.Biological agents for the treatment of uveitis.Light on the horizont: biologicals in Behçet uveitis.Adalimumab for the treatment of Behçet's disease: experience in 19 patients.Differential diagnosis and management of Behçet syndrome.Systemic treatment of vitreous inflammation.Current and future treatments for Behçet's uveitis: road to remission.Approaches to immunosuppression in Behçet's disease.Systemic treatments for noninfectious vitreous inflammation.Behçet's syndrome pathophysiology and potential therapeutic targets.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.Behçet syndrome: from pathogenesis to novel therapies.Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions.New therapeutic solutions for Behçet's syndrome.
P2860
Q24193450-DE97B60E-FF9A-46BD-88E8-C5403BD88178Q24654208-CF76CE0E-0D4E-4DDB-90FF-55B5A3350FBFQ24675071-C9155B4C-0515-47C6-93E0-6C8DBFE3FC24Q24804631-9C651D14-0A35-4A04-8689-FC257FDD96B2Q26799767-49156275-C61C-418B-9D9B-31F00D8F731EQ27000669-2DA6FC57-85D1-42DE-B70B-36A60C95E424Q28070375-B5C0D186-866D-4827-814B-17A253F1BE98Q28279953-D7512863-02A6-42EB-94E1-F5F7DBB4F59DQ33908217-46E678D4-923A-4AA1-99E7-7AA0DACBD558Q34311953-45C0790A-25EB-4AC7-8EF0-FCF8EFDCE317Q34430267-93782B25-7915-4457-964D-EB1D9973A04BQ34494125-24B33CC4-79E8-45DA-B75E-475742A55994Q35295186-D4D5CAE9-2877-4FD2-A0CB-58F0C05599F7Q35680592-D4CD23D1-3228-4C6A-B452-0939CA2FFC49Q35763133-5829E069-B899-42FA-AFC8-1479BFDD072FQ35868282-8365BEC0-5668-4955-B5A4-51CAD2A0630FQ36086202-53389DA9-715B-40D5-810D-552AA02DA125Q36501675-77A7D5AF-5A52-42AB-8325-C825C89A2A0DQ36920297-59AE2B19-9FBE-4B66-979D-14F0A5010764Q37146101-0DFD01A6-2793-48E9-B445-4B2C7CF22C33Q37230348-B0880A2E-CE6E-4732-A539-C666A0EC8887Q37307804-B75A5016-93BC-470E-9E45-90BE05078CDFQ37406596-A6F8BCB9-9449-4401-B36B-62F16D2987D6Q37443718-183F7914-A27E-4895-8B44-178934C3A7A6Q37650221-6679CF3C-6A65-46FE-B2D7-B1B9C6DB6334Q37711766-7C9AB36E-2C78-48DC-8A2E-80C2C1355AE4Q37712230-F8B3AE3A-B7E8-4EF5-BE66-B9BA407C11FAQ37984565-66716A3F-D2B9-4D11-8056-D01C7FF3026DQ38004097-6707D1E5-9798-4548-9886-07009698B373Q38020828-C7E25B54-4277-4D14-86BE-BB423104F761Q38046118-6F7A4564-8FDA-4F0A-8ABD-5E7D1B48432DQ38048774-6E7160EF-2BF4-4CFD-ACD0-00388BD03CC5Q38111308-2930A9B8-6ECB-44C3-8430-6FF20EF94CDAQ38119551-E3214769-88AB-4A53-A5E6-AFAC462BDA61Q38172090-6F0F7C96-A24C-4C12-B4E5-785D2AB0B2EBQ38177749-E164EBF7-1A5B-4A45-B102-F08CA6DC44DAQ38250103-D299F396-A94C-4CCB-9952-79E7162C31CBQ38275100-5743E84E-F559-4B1D-BA5D-4A7A9C3D07DCQ38807791-6C9E2E8D-D3F9-49CF-A105-46C2A38FB8CAQ38830790-3FFE867E-E03C-47C8-855B-5E745C2BF5DA
P2860
Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@ast
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@en
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@nl
type
label
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@ast
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@en
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@nl
prefLabel
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@ast
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@en
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@nl
P2093
P1433
P1476
Interferon alfa-2a in the trea ...... rolled and double-blind study.
@en
P2093
Cicek Durusoy
Erdal Basaran
Erkan Alpsoy
Sahin Yazar
Yilmaz Ozgurel
P304
P356
10.1001/ARCHDERM.138.4.467
P50
P577
2002-04-01T00:00:00Z